Spots Global Cancer Trial Database for auy922
Every month we try and update this database with for auy922 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan | NCT01132625 | Advanced Solid ... | AUY922 | 20 Years - | Novartis | |
| Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer | NCT01084330 | Advanced Gastri... Gastro-esophage... | AUY922 Docetaxel Irinotecan | 18 Years - | Novartis | |
| Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients | NCT01402401 | Advanced Gastri... | AUY922 Trastuzumab | 18 Years - | Novartis | |
| PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer | NCT01613950 | Stomach Neoplas... | AUY922 BYL719 | 18 Years - | Novartis | |
| Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan | NCT01132625 | Advanced Solid ... | AUY922 | 20 Years - | Novartis | |
| Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR | NCT01854034 | Non Small Cell ... | AUY922 | 18 Years - | Massachusetts General Hospital | |
| Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients | NCT01402401 | Advanced Gastri... | AUY922 Trastuzumab | 18 Years - | Novartis | |
| AUY922 for Advanced ALK-positive NSCLC | NCT01752400 | Non Small Cell ... | AUY922 | 18 Years - | Massachusetts General Hospital | |
| Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | NCT01294826 | Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal... Adenocarcinoma ... Adenocarcinoma ... | AUY922 Cetuximab | 18 Years - | Swedish Medical Center | |
| A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients | NCT01389583 | Gastrointestina... | AUY922 | 20 Years - 75 Years | National Health Research Institutes, Taiwan | |
| AUY922 in Patient With Stage IV NSCLC | NCT01922583 | Non-small Cell ... | AUY922 | 20 Years - | National Taiwan University Hospital | |
| Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients | NCT01402401 | Advanced Gastri... | AUY922 Trastuzumab | 18 Years - | Novartis | |
| AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer | NCT01361945 | Breast Cancer Metastatic Brea... HER-2 Positive ... ER Positive Bre... | AUY922 | 18 Years - | Texas Tech University Health Sciences Center, El Paso | |
| A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients | NCT01389583 | Gastrointestina... | AUY922 | 20 Years - 75 Years | National Health Research Institutes, Taiwan | |
| Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | NCT01294826 | Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal... Adenocarcinoma ... Adenocarcinoma ... | AUY922 Cetuximab | 18 Years - | Swedish Medical Center | |
| An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | NCT01646125 | Advanced Non Sm... | AUY922 Docetaxel Pemetrexed | 18 Years - | Novartis | |
| Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy | NCT01484860 | Adenocarcinoma ... Metastatic Dise... | AUY922 | 18 Years - | University Health Network, Toronto | |
| PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer | NCT01613950 | Stomach Neoplas... | AUY922 BYL719 | 18 Years - | Novartis | |
| Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | NCT01294826 | Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal... Adenocarcinoma ... Adenocarcinoma ... | AUY922 Cetuximab | 18 Years - | Swedish Medical Center | |
| Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer | NCT01772797 | Anaplastic Lymp... Non-small Cell ... | LDK378 AUY922 | 18 Years - | Novartis | |
| HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET | NCT01668173 | Myeloproliferat... | AUY922 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | NCT01271920 | Advanced HER2-p... | AUY922 Trastuzumab | 18 Years - | Novartis | |
| An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | NCT01646125 | Advanced Non Sm... | AUY922 Docetaxel Pemetrexed | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
